Back to today’s briefing

Story perspectives

Biotech Resurgence: Major Acquisitions Amid Mixed Results

1/29/2025

38 7

Summary

Story summary

Global biotech is experiencing a resurgence, with giants like Johnson & Johnson, Eli Lilly, and GSK making significant acquisitions, marking a turnaround from a steep 47% drop in 2024. Dimerix shines with robust cash reserves as trials advance, while Pacific Edge gains a crucial two-month extension for US reimbursement. Meanwhile, Percheron grapples with board challenges after a disappointing drug trial.

1 of 1

Story summary

Global biotech is experiencing a resurgence, with giants like Johnson & Johnson, Eli Lilly, and GSK making significant acquisitions, marking a turnaround from a steep 47% drop in 2024. Dimerix shines with robust cash reserves as trials advance, while Pacific Edge gains a crucial two-month extension for US reimbursement. Meanwhile, Percheron grapples with board challenges after a disappointing drug trial.